AXO-LENTI-PD: POTENTIALLY TURNING BACK THE CLOCK FOR PATIENTS WITH PARKINSON’S DISEASE
AXO-Lenti-PD achieved up to 10-fold increases in dopamine + L-Dopa production and increased AADC activity compared to ProSavin ® (OXB-101)
Watch the following video of the older ProSavin treatment
• Cohort 2 (n=2 evaluable patients): Positive 6-month data demonstrating 21-point mean improvement from baseline in UPDRS III “OFF” score
• Cohort 3 (4.2 x 107 TU*) is three times more than Cohort 2 (1.4 x 107 TU*) *Target dose
• Sio plans to move to the third higher dose cohort in the study after which it expects to initiate the randomised, sham-controlled part of the SUNRISE-PD Phase 2 study in 2022
• Sales of products to treat Parkinson’s disease in the 7 major markets reached $3.1bn in 2016 and is forecast tovreach $8.4bn by 2026
Thursday, October 21, 2021 Poster Presentation Details:
Presentation Title: Phase 1/2 Open-label Dose Evaluation Study of AXO-Lenti-PD Gene Therapy for Parkinson’s Disease: Efficacy, Safety, and Tolerability Data up to 24 Months Poster Number: P254 Presenting Author: Gavin Corcoran, MD, Chief R&D Officer of Sio Gene Therapies
A poster review of patient-level data up to 24 months from the Phase 1/2 study of AXO-Lenti-PD gene therapy for the treatment of Parkinson’s disease.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.